New drug ESK981 takes on tough cancers in Mid-Stage trial

NCT ID NCT05988918

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 14, 2026 · Updated 6 times

Summary

This study tests an experimental drug called ESK981 in people with advanced pancreatic cancer, certain neuroendocrine tumors, or neuroendocrine prostate cancer. Participants take ESK981 capsules in a 5-days-on, 2-days-off cycle. The main goal is to see if the drug can keep the cancer from growing for at least 4 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Barbara Ann Karmanos Cancer Institute
WITHDRAWN

Detroit, Michigan, 48201, United States
Rogel Cancer Center
ACTIVE_NOT_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADENOSQUAMOUS CARCINOMA GASTROINTESTINAL NEUROENDOCRINE CARCINOMA GASTROINTESTINAL NEUROENDOCRINE TUMOR NEUROENDOCRINE PROSTATE CARCINOMA PANCREATIC ADENOCARCINOMA PANCREATIC NEUROENDOCRINE CARCINOMA PANCREATIC NEUROENDOCRINE TUMOR